A Phase 3 interventional study of HIP2602 + HPP2602-2 and HPP2602-1 + HPP2602-2 in Erectile Dysfunction, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 1 site in South Korea. Open to male participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment
A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
701 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
This study's planned enrollment of 225 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Browse Erectile Dysfunction studies →Hanmi Pharmaceutical Company Limited is the lead sponsor of 190 studies on the registry; 11 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Visit 1 (screening)
Visit 2 (Randomization)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily administration, oral
Drug: HIP2602 + HPP2602-2
Daily administration, oral
Drug: HPP2602-1 + HPP2602-2
Daily administration, oral
Drug: HGP1201 + HPP2602-1
Test drug
Control drug
Active Comparator
Change of IIEF-EF domain score from baseline after 12 weeks
Time frame: baseline, 12 weeks
Change of IIEF-EF domain score from baseline after 6 weeks
Time frame: baseline, 6 weeks
Change of IIEF-OF domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF-SD domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF-IS domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF-OS domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF Question 3 score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF Question 4 score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
The proportion or participants achieving IIEF-EF domain score ≥ 26 after 6, 12 weeks
Time frame: 6 weeks, 12 weeks
The proportion (%) of participants who responded "Yes" to Sexual Encounter Profile (SEP) Questions 1, 2, 3, 4, and 5 at Weeks 6 and 12 compared with baseline
Time frame: baseline, 6 weeks, 12 weeks
The proportion of participants who responded "Yes" to Global Assessment Question (GAQ) at Week 12
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited →